
Therapeutic Potential of Silmitasertib Observed in Huntington Disease Mouse Model
Newly presented preclinical research suggests that silmitasertib (CX4945), an FDA-designated orphan drug for cancer, may offer therapeutic benefits for Huntington disease (HD) by reducing mutant huntingtin (mHTT) aggregation and improving motor function in …